Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Multicenter, Open-labeded Study To Evaluate Efficacy and Safety of TG-2349 in Combination With DAG181 and Ribavirin for 12 Weeks of Treatment in HCV Genotype I Infected Patients

NCT04155515 is registered in ClinicalTrials.gov with Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT04155515
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04155515 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Multicenter, Open-labeded Study To Evaluate Efficacy and Safety of TG-2349 in Combination With DAG181 and Ribavirin for 12 Weeks of Treatment in HCV Genotype I Infected Patients
Lead sponsor
Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
June 13, 2019
Completion date
August 11, 2020
Enrollment
370 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatics c virus (hcv) genotype 1, cirrhosis, non-cirrhotic, treatment naïve